Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial

By sjmartinez • June 4, 2024

Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. J Crohns Colitis. 2024 Jun 3;18(6):885-894. doi: 10.1093/ecco-jcc/jjae007. PMID: 38245818; PMCID: PMC11147797.

Tags: Cedars Sinai DoM, Digestive Diseases, endoscopic improvement–histologic remission, Etrasimod, mucosal healing, Publications, S1P receptor modulator, ulcerative colitis

Serum Potassium Monitoring Using AI-Enabled Smartwatch Electrocardiograms

Chiu IM, Wu PJ, Zhang H, Hughes JW, Rogers AJ, Jalilian L, Perez M, Lin CR, Lee CT, Zou J, Ouyang D. Serum Potassium Monitoring[...]

Whole-genome sequencing in 333,100 individuals reveals rare non-coding single variant and aggregate associations with height

Hawkes G, Beaumont RN, Li Z, Mandla R, Li X, Albert CM, Arnett DK, Ashley-Koch AE, Ashrani AA, Barnes KC, Boerwinkle E, Brody JA, Carson[...]

Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study

Syal G, Mishkin DS, Banty A, Lee S, Fontelera N, Hampton M, Ziring D, Fleshner PR, Melmed GY. Effectiveness of Oral Tofacitinib in Chronic Pouchitis:[...]